Clinical correlates of augmentation/combination treatment strategies in major depressive disorder

Acta Psychiatrica Scandinavica
Markus DoldSiegfried Kasper

Abstract

This multicenter, multinational, cross-sectional study aimed to investigate clinical characteristics and treatment outcomes associated with augmentation/combination treatment strategies in major depressive disorder (MDD). Sociodemographic, clinical, and treatment features of 1410 adult MDD patients were compared between MDD patients treated with monotherapy and augmentation/combination medication using descriptive statistics, analyses of covariance (ancova), and Spearman's correlation analyses. 60.64% of all participants received augmentation and/or combination strategies with a mean number of 2.18 ± 1.22 simultaneously prescribed psychiatric drugs. We found male gender, older age, Caucasian descent, higher weight, low educational status, absence of occupation, psychotic symptoms, melancholic and atypical features, suicide risk, in-patient treatment, longer duration of hospitalization, some psychiatric comorbidities (panic disorder, agoraphobia, obsessive-compulsive disorder, and bulimia nervosa), comorbid somatic comorbidity in general and concurrent hypertension, thyroid dysfunction, diabetes, and heart disease in particular, higher current and retrospective Montgomery and Åsberg Depression Rating Scale total scores, treatmen...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
May 4, 2005·European Archives of Psychiatry and Clinical Neuroscience·Mazda AdliMichael Bauer
Aug 3, 2005·Archives of General Psychiatry·Lars Vedel KessingPer Kragh Andersen
Jan 5, 2006·The American Journal of Psychiatry·Madhukar H TrivediUNKNOWN STAR*D Study Team
Mar 24, 2006·The New England Journal of Medicine·Madhukar H TrivediUNKNOWN STAR*D Study Team
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Aug 19, 2009·The American Journal of Psychiatry·J Craig Nelson, George I Papakostas
Jan 6, 2010·Archives of General Psychiatry·Ramin Mojtabai, Mark Olfson
Jul 3, 2013·BMJ : British Medical Journal·Andrea CiprianiJohn R Geddes
Jul 25, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders
Sep 21, 2013·The International Journal of Neuropsychopharmacology·H-J MöllerR Grohmann
Mar 5, 2014·CNS Drugs·Michael BauerMaximilian Pilhatsch
Apr 26, 2015·Journal of Affective Disorders·Yu HayasakaToshi A Furukawa
Nov 17, 2016·International Journal of Psychiatry in Clinical Practice·Markus Dold, Siegfried Kasper
Jul 8, 2017·The Journal of Clinical Psychiatry·Tobias GerhardMark Olfson

❮ Previous
Next ❯

Citations

Nov 24, 2018·The British Journal of Psychiatry : the Journal of Mental Science·Chiara FabbriAlessandro Serretti
Jul 26, 2019·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Lucie BartovaSiegfried Kasper
Nov 4, 2020·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Siegfried KasperAllan H Young
Dec 15, 2020·Acta Psychiatrica Scandinavica·Markus Dold, Siegfried Kasper
Feb 21, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Markus DoldSiegfried Kasper
Nov 13, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·Giuseppe FanelliChiara Fabbri

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA
pharmacotherapy
sedation

Software Mentioned

spss

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here